🔗 https://xmrrwallet.com/cmx.pbit.ly/3FsFgOW It's her big game. You want to be there AND be fully present. Living with disease makes that difficult by holding you back. Over time, the sounds of disease - doctor visits, tests, managing medication, saying “no” to life’s most important moments - mute the joy of life. But what happens when you #SilenceDisease? #AmplifyLife #RNAi #RNAiTherapeutics
Alnylam Pharmaceuticals
Biotechnology Research
Cambridge, Massachusetts 242,411 followers
Alnylam is the leading RNAi therapeutics company. We're a fast-growing biopharma with a deep pipeline and global reach.
About us
SILENCE DISEASE. AMPLIFY LIFE.™ Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them. Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of (RNAi) therapeutics possible. In 2018, our first commercial medicine, and the world’s first RNAi therapeutic was approved. Since then, four more Alnylam-developed medicines have been approved and we’re hard at work developing new therapies to treat both rare and prevalent diseases. We are a global and diverse company of 2,500+ people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we’re consistently ranked as a top employer by The Boston Globe (2015-24), Science Magazine (2018-24), Fast Company (Best Workplaces for Innovators 2020-24) and LinkedIn (2024). We are based in Cambridge, Massachusetts (U.S.), with offices throughout North America, Europe, Asia, and South America. See our social media community guidelines: https://xmrrwallet.com/cmx.pbit.ly/2FcRhJy. Please note: If you wish to report an adverse event or product complaint, please email medinfo@alnylam.com or you may call us using the following telephone numbers: for North America, 877.ALNYLAM (877.256.9526), for Europe, +31 20 369 7861
- Website
-
http://xmrrwallet.com/cmx.pwww.alnylam.com
External link for Alnylam Pharmaceuticals
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Public Company
- Founded
- 2002
- Specialties
- Biotech, Pharmaceuticals, Biopharma, Drug Development, Rare Diseases, and RNAi
Locations
Employees at Alnylam Pharmaceuticals
Updates
-
We'll be sharing 2nd Quarter 2025 financial results this Thursday, 7/31 at 8:30 AM ET, during a LIVE webcast. Register here: https://xmrrwallet.com/cmx.pbit.ly/374c75E and access the replay at the same link later in the day. #RNAi #RNAitherapeutics #siRNA
-
-
Ziggy’s journey with primary #hyperoxaluria type 1 (#PH1) comes with many challenges—but through it all, he continues to embrace life with energy, curiosity and joy. Since Ziggy’s diagnosis in 2017, increased PH1 awareness and advancements have brought more hope and support for families affected by this #raredisease. Watch Ziggy’s story at: https://xmrrwallet.com/cmx.pbit.ly/4077xSE. Learn more about PH1 support and resources at Oxalosis and Hyperoxaluria Foundation.
-
🔗 https://xmrrwallet.com/cmx.pbit.ly/3DEiiUB Doctors appointments, tests, pharmacy visits, medication routines - the sounds of these things make living with disease noisy. But when disease is silenced, these things become less prevalent and the everyday joys of life can be amplified. We've pioneered #RNAi therapeutics to do just that - #SilenceDisease to #AmplifyLife.
-
Rapid advancement of the field of RNA interference (RNAi) is changing the way that medicine treats both rare and more common diseases. Alnylam, having pioneered this innovative class of gene-silencing medicines, is proud to be leading the charge. 🔗 https://xmrrwallet.com/cmx.plnkd.in/eG6PePCU Sponsored content with Nature Portfolio. #RNAi #RNAiTherapeutics #siRNA #GeneSilencing
-
-
Ziggy’s path living with primary #hyperoxaluria type 1 (#PH1) has been one of unimaginable resilience, marked by two kidney transplants, a liver transplant and countless moments of uncertainty with this #raredisease. For his parents, Jackie and Colin, the Rowan tree they planted represents more than hope—it’s a living symbol of Ziggy’s strength, rooted in love. Watch Ziggy’s PH1 story: https://xmrrwallet.com/cmx.pbit.ly/4077xSE
-
Women's pain is often blamed on stress, hormones, or branded as "normal," which can lead to delayed diagnosis of serious conditions. That was the case for Donna, whose journey to a diagnosis of acute hepatic #porphyria (AHP) spanned over 10 years. Recognizing and investigating seemingly disparate symptoms such as those experienced by people with AHP can help patients like Donna regain control of their lives. Read more about her symptoms and story: https://xmrrwallet.com/cmx.pbit.ly/3Xs0KBp #raredisease #womenshealth
-
-
Living with disease is noisy. Day-to-day life is filled with the sounds of endless doctor appointments, tests, managing medication and having to decline invitations to do the things you really want to do. Over time, these sounds mute the joy of life. But what happens when disease is silenced? Learn more: https://xmrrwallet.com/cmx.pbit.ly/4iG8rw6 #SilenceDisease #AmplifyLife #RNAi #RNAiTherapeutics
-
ICYMI: Our 2024 Corporate Responsibility Report highlights how Alnylam is making an impact. From supporting patients and employees to advancing science, uplifting communities, and protecting the planet, our work reflects our values and our ambition to give back to society. Explore the full report: https://xmrrwallet.com/cmx.pbit.ly/3SHe02n #CorporateResponsibility #CSR #ESG
-
Ziggy’s parents, Jackie and Colin, knew something wasn’t right. Their persistence helped lead to their newborn son’s diagnosis of primary #hyperoxaluria type 1 (#PH1), a genetic #raredisease. See how Jackie and Colin advocated for Ziggy: https://xmrrwallet.com/cmx.pbit.ly/4077xSE